SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Metrics to compare | SYNACT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYNACTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −2.0x | −0.6x | |
PEG Ratio | −0.24 | −0.04 | 0.00 | |
Price/Book | 6.0x | 6.3x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.4x | |
Upside (Analyst Target) | 43.0% | 271.3% | 41.8% | |
Fair Value Upside | Unlock | −6.6% | 4.8% | Unlock |